Early-onset colorectal cancer statistics: the under-50 rise clinicians keep missing

She was 41, two kids in elementary school, and she had been told three times that rectal bleeding was "probably hemorrhoids." The first clinician treated her empirically. The second ordered iron studies after her hemoglobin fell, then attributed the anemia to heavy periods without a pelvic exam that would have contradicted that story. The third finally ordered a colonoscopy. She had a rectal adenocarcinoma that had already reached regional nodes.

Nothing about her presentation was exotic. Blood in the stool, progressive iron deficiency, and a change in bowel caliber are textbook red flags. What failed her was the age assumption still embedded in a lot of clinical reasoning: colorectal cancer is a disease of older adults, so young adults with the same symptoms get reassurance and a stool softener.

That assumption is outdated in a way the surveillance data now makes hard to ignore. According to the American Cancer Society's Colorectal Cancer Statistics, 2026 report (Siegel and colleagues in CA: A Cancer Journal for Clinicians), incidence in adults ages 20-49 has been rising about 3% per year from 2013 through 2022. In 2022, 22% of U.S. colorectal cancers were diagnosed in people younger than 55. That is twice the 11% share recorded in 1995. Colorectal cancer is now the leading cause of cancer death in adults under 50.

This page pulls the numbers a reporter or clinician can quote on deadline: how large the under-50 burden is in women, how late these cancers tend to be caught, what the screening-age change to 45 has and has not fixed, and what survival still looks like when stage is the main variable.

Age group	Women	Men	Total	Share of all cases
Birth to 49	11,970	12,670	24,640	16%
50-64	19,800	27,800	47,600	30%
65 and older	42,920	43,690	86,610	55%
All ages	74,690	84,160	158,850	100%

Source: Siegel et al., Colorectal cancer statistics, 2026, Table 1. Estimates rounded to the nearest 10. Colon totals include appendiceal cancer; incidence rates elsewhere in the report generally exclude the appendix.

Year	Death rate per 100,000
2010	15.55
2012	14.80
2014	14.28
2016	13.90
2018	13.39
2020	12.87
2022	12.74
2023	12.67

Source: NCI SEER Cancer Stat Facts: Colorectal Cancer (U.S. mortality). Overall death rates continue to fall; Siegel et al. (2026) report mortality still rising about 1% per year in adults younger than 50 since 2004.

Measure	Estimate
Hematochezia (blood in stool)	45% pooled prevalence
Abdominal pain	40% pooled prevalence
Altered bowel habits	27% pooled prevalence
Mean time, symptom onset to diagnosis	6.4 months
Median time, symptom onset to diagnosis	4 months

Source: Demb et al., JAMA Network Open, 2024. Systematic review and meta-analysis of 81 studies including more than 24.9 million patients younger than 50 years.

The under-50 trend

Colorectal cancer still looks like a success story on the surface. SEER puts the age-adjusted rate of new cases at 37.6 per 100,000 men and women per year (2019-2023). The death rate is 12.7 per 100,000 (2020-2024). For diagnoses in 2016-2022, five-year relative survival is 65.4%. Lifetime risk is about 3.9%. Roughly 1.48 million people were living with a colorectal cancer history in 2023. Since the mid-1980s, the long arc has been downward.

The under-50 story runs the other way. Siegel and colleagues report that incidence ages 20-49 rose 1%-2% annually from the mid-1990s. Then it accelerated. From 2013 to 2022 the rise was about 3% per year. Part of that recent acceleration is a localized-stage bump after screening expanded into ages 45-49. Yet even while that bump was happening, regional- and distant-stage disease in 20- to 49-year-olds kept climbing about 3% per year for more than a decade. Mortality under 50 has risen about 1% annually since 2004.

The demographic shift is easy to quote. In 2022, 22% of colorectal cancers were diagnosed under age 55. That is double the 11% in 1995. Nearly half (45%) of new diagnoses now fall under age 65, up from 27% in 1995. ACS's earlier Colorectal Cancer Facts & Figures 2023-2025 had already shown the under-55 share doubling from 11% in 1995 to 20% in 2019. Siegel et al. note the same early-onset rise in at least 14 countries where rates at 50 and older are stable or falling. Inside the United States, every major racial and ethnic group is affected. From 2013 to 2022 the annual rise was about 2% in Black adults, 3% in White, Asian American/Native Hawaiian/Pacific Islander and American Indian/Alaska Native adults, and 4% per year in Hispanic adults.

The anatomic pattern matters clinically. Early-onset disease is disproportionately left-sided: distal colon, especially sigmoid, and rectum. In ages 20-49, from 1998 to 2022, sigmoid colon incidence nearly doubled (2.1 to 3.7 per 100,000). Rectal cancer nearly doubled too (3.6 to 6.6 per 100,000). Proximal tumors rose only 26% in that same window. Rectal cancer now accounts for 32% of all colorectal cancers, up from 27% in the mid-2000s. Left-sided tumors present with bleeding and caliber change more often than right-sided tumors. That helps if someone is listening. It harms patients if the default is still "hemorrhoids until proven otherwise" in a 38-year-old.

How many women, and how young

For 2026, ACS projects 158,850 new invasive colorectal cancer cases and 55,230 deaths in the United States. Of those new cases, 24,640 (16%) are expected from birth through age 49. Women account for 11,970 of those young-onset cases. Men account for 12,670. Under age 50 the sex gap is narrow. Incidence in men is only about 19% higher than in women, compared with 44% higher at ages 50-64 and 32% higher overall (40.5 versus 30.7 per 100,000). Distal colon cancer rates under 50 are essentially the same in women and men. ACS projects 3,890 deaths under 50 in 2026, including 1,640 in women. Older adults still carry most of the absolute burden and most of the progress. Younger adults are carrying a growing share of both.

Genetics explain only part of this. Siegel et al. estimate that 16%-20% of colorectal cancers diagnosed before 50 reflect predisposing germline conditions such as Lynch syndrome. That fraction is higher than in older adults, which is why family history and genetic counseling still matter. The large majority of early-onset cases are still sporadic. Obesity and inactivity contribute, along with diet, but those factors do not fully explain a birth-cohort effect strongest in the rectum and sigmoid. Researchers are now looking at gut microbiome change and at ultra-processed foods and antibiotics, among other mid-century shifts. The data here is weaker than you'd hope if you want a single causal lever.

Women's health clinics often see these patients first for other reasons: iron-deficiency anemia, menstrual irregularity, postpartum bleeding questions, or "GI symptoms" attributed to stress. Our reviews of iron-deficiency anemia in women and healthcare access disparities describe how often anemia is explained away as menstrual loss without a complete evaluation. Early-onset colorectal cancer is one of the diagnoses that hides inside that habit.

Stage at diagnosis in younger patients

Stage still decides most outcomes. Siegel et al. report that three in four patients younger than 50 are diagnosed with advanced disease. Distant metastases are already present in 27% of under-50 cases. In older age groups that figure is 21%-23%. ACS's 2023-2025 facts report had already documented a broader stage shift. Regional or distant disease rose from 52% of colorectal cancers in the mid-2000s to 60% in 2019 across ages.

Less screening before 45 is the structural reason. Diagnostic delay is the other. Younger adults wait longer for the correct test. Clinicians underestimate cancer risk, and insurance and referral barriers hit harder earlier in adulthood. One study cited by Siegel et al. found about a 40% longer time to diagnosis under age 50 than in older patients. Advanced stage is not hopeless in a 42-year-old. Younger patients have better stage-specific survival, but it still means more multimodality treatment, more fertility and sexual-function consequences, and more years of survivorship morbidity. Stage migration from delay is the difference between a polypectomy conversation and a permanent ostomy conversation.

Why screening now starts at 45

Average-risk screening used to start at 50. ACS moved its recommendation to 45 in 2018. The USPSTF followed in May 2021. It gave ages 45-49 a Grade B recommendation and kept Grade A for ages 50-75 (Grade C for selective screening at 76-85). Those recommendations apply to asymptomatic average-risk adults: no prior colorectal cancer or advanced polyps, no inflammatory bowel disease, no high-risk genetic syndrome.

The age change responded directly to the early-onset incidence curve. Siegel et al. note a subsequent rise in localized-stage diagnoses among previously unscreened 45- to 49-year-olds, the same kind of prevalent-case bump older adults saw when colonoscopy expanded in the early 2000s. That is what screening is supposed to do: move cancers left on the stage distribution before symptoms force the diagnosis.

Uptake is unfinished. In 2023 National Health Interview Survey data summarized by ACS, 65% of adults 45 and older were up to date with colorectal cancer screening. For adults 45-49, it was only 37%. Women were essentially even with men overall (65% versus 64%). The gap is age, not sex. Screening also does not cover cases that appear before 45. A 38-year-old with rectal bleeding is not a screening failure. She is a symptom-management failure if the workup stops at reassurance.

For context on how screening age shifts play out in other women's cancers, see our pages on breast cancer screening statistics and cervical cancer and HPV screening. Guidelines move first; coverage and behavior catch up later.

Symptoms, dismissal, and diagnostic delay

The 2024 JAMA Network Open systematic review by Demb and colleagues is the cleanest current source on presentation. It pooled 81 studies and more than 24.9 million people younger than 50. The most common findings were hematochezia (pooled prevalence 45%), abdominal pain (40%) and altered bowel habits (27%). Hematochezia was associated with at least a fivefold higher likelihood of early-onset colorectal cancer. Anemia and abdominal pain also raised risk, with effect estimates that varied by study.

Time to diagnosis shows the age bias most clearly. Demb et al. found a mean of 6.4 months from symptom onset to diagnosis (range 1.8-13.7 months across 23 studies). The median was 4 months (range 2.0-8.7 across 16 studies). Delays of four to six months were common. That is long enough for stage migration. It is also long enough for a woman to be told more than once that her symptoms are dietary, stress-related, hemorrhoidal or menstrual.

Most of those dismissals are not malicious. Colorectal cancer is still far less common at 35 than at 65. Hemorrhoids and IBS are common. Heavy menses cause anemia. "Common things are common" is usually right. It stops being right when the prior shifts and the red flags stack. Rectal bleeding plus iron deficiency plus progressive caliber change should not be waved away in the fourth decade of life.

Women face an extra layer of misattribution. Bowel symptoms get folded into gynecologic narratives. Fatigue gets folded into motherhood or mood. Patients who track cycles on a period calculator or who are sorting out a late period may present first in reproductive-health settings. If that clinician does not put colorectal cancer on the differential, the referral chain never starts. Family history is still under-collected: a first-degree relative with colorectal cancer, especially before age 50, changes both screening start age and how aggressively symptoms are worked up.

What survival looks like by stage and age

Five-year relative survival for colorectal cancer overall has moved from about 50% in the mid-1970s to 65% for diagnoses in 2015-2021, per Siegel et al. SEER's all-stage figure for 2016-2022 is 65.4%. Stage dominates. Survival is about 92% for localized disease and 15% for distant disease. For regional-stage disease it ranges from 81% under age 50 to 69% at 65 and older.

Younger patients do better stage for stage. For distant disease, five-year relative survival is about 23% under 50. It is 17% at ages 50-64 and 10% at 65 and older. That is not a reason for comfort. It is a reason not to waste the advantage younger physiology still offers by diagnosing late. Sex differences overall are small (about 65% in women and 64% in men), though women retain a clearer edge in rectal cancer (69% versus 65%).

Survival statistics hide survivorship cost. Siegel et al. note that fewer than half of patients diagnosed before 50 discuss fertility preservation with a physician before treatment. Rectal surgery and systemic therapy, including radiation, can affect sexual function, continence, body image and future childbearing. Our page on ovarian and endometrial cancer statistics covers parallel issues in other gynecologic cancers. Early-onset colorectal cancer needs the same counseling standard. As of January 1, 2025, more than 1.4 million people in the United States were colorectal cancer survivors. A growing fraction was diagnosed young. For them, long-term neuropathy, bowel dysfunction and financial strain are expected, not rare.

What clinicians and patients can do

For average-risk adults, the number that matters is 45. If you are 45 or older and not up to date, schedule screening: colonoscopy, FIT, stool DNA-FIT or another recommended strategy. Complete the follow-up colonoscopy after a positive stool test. The 37% up-to-date rate in ages 45-49 means most newly eligible adults still have not done this.

Under 45, screening is not the main lever unless family history or a syndrome moves the start age earlier. Symptom recognition is. Rectal bleeding, unexplained iron-deficiency anemia, persistent abdominal pain and a lasting change in bowel habits deserve a diagnostic plan with a stop date, not open-ended reassurance. For clinicians in women's health and primary care, the change is concrete. Do not use age alone to close the differential. Ask about family history. Check a hemoglobin when fatigue is the complaint. Refer for colonoscopy when red flags persist.

The vignette at the top of this page is a composite, but the sequence is one I have watched more than once. The statistics do not make every case preventable. They do make the old age cutoff indefensible as a reason to wait.

Frequently asked questions